Login to Your Account

No A+, but AAC Passes Pfizer's First-in-Class JAK Inhibitor

By Mari Serebrov
Washington Editor

Thursday, May 10, 2012
An FDA advisory committee gave Pfizer Inc.'s tofacitinib passing grades as an arthritis treatment Wednesday, but it piled on the homework.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription